MeRT (Magnetic e-Resonance Therapy) is a personalized form of transcranial magnetic stimulation that uses brain wave recordings and heart rhythm data to customize treatment for each patient. Unlike standard TMS, which applies the same protocol to everyone with a given condition, MeRT adjusts the magnetic pulse frequency and stimulation location based on your individual brain activity. It’s marketed for conditions including PTSD, depression, traumatic brain injury, and autism, though it is not FDA-approved for most of these uses.
How MeRT Differs From Standard TMS
Standard repetitive TMS (rTMS) targets the same brain region in every patient, typically the left prefrontal cortex for depression, and uses fixed frequencies like 10 Hz or 50 Hz. MeRT takes a different approach. It uses a quantitative EEG (qEEG) brain map to find areas where brain activity appears irregular, then targets those specific locations with magnetic pulses tuned to match your natural alpha brain wave frequency, typically somewhere between 9 and 12 Hz.
The idea behind this customization is that everyone’s brain operates at slightly different frequencies. By matching the stimulation to your individual rhythm, and factoring in data from a simultaneous heart rhythm recording, MeRT aims to “re-sync” brain regions that aren’t communicating well with each other. A retrospective comparison published in SciTechnol found that MeRT protocols varied from patient to patient in pulse count, frequency, and stimulation site, while standard rTMS protocols were uniform across patients.
What a Treatment Course Looks Like
Before any stimulation begins, you go through an initial assessment that combines a qEEG and an EKG recorded at the same time. A technician places a cap with electrode holes on your head, applies conductive gel to each site, clips small sensors to your earlobes, and places an electrode on your chest. The appointment is scheduled for about 45 minutes for adults, though the actual recording only takes around 15 minutes. For children, clinics typically allow up to an hour. This data produces a “brain map” that shows which areas may be out of sync.
Once your personalized protocol is designed, treatment sessions run approximately 45 minutes each and are typically scheduled daily on weekdays. The qEEG is repeated periodically throughout treatment so clinicians can adjust the protocol as your brain activity changes. A full course generally runs several weeks, and some providers offer packages of visits at varying price points.
Cost and Insurance Coverage
MeRT is primarily a self-pay treatment. Because standard rTMS is FDA-cleared only for depression and obsessive-compulsive disorder, insurance reimbursement for MeRT is inconsistent at best. Some patients have reported partial reimbursement for the EEG recordings, clinical evaluations, or treatment sessions depending on their plan, but Medicare patients have generally reported no reimbursement for the treatment itself. Clinics typically offer payment packages, though specific pricing is rarely published. Anecdotal reports from patients and clinic descriptions suggest a full course can run several thousand dollars out of pocket.
Evidence for PTSD and Depression
The strongest published data for MeRT comes from military populations. A 2024 study in Frontiers in Psychiatry tracked active-duty special operations service members through a 30-session treatment program. PTSD symptom scores dropped an average of 37%, falling from 42.9 to 27 on a standard PTSD checklist. That final average landed below the clinical threshold of 33, meaning many participants no longer met the scoring criteria for PTSD at the end of treatment. Of those who started above the PTSD cutoff, 42% scored below it by the final session.
Depression scores also improved. Among service members who started with clinically significant depression, 46% fell below the clinical threshold after treatment. Cognitive function showed the largest relative gains, with a 45.5% reduction in scores measuring perceived cognitive difficulties like memory lapses and trouble concentrating.
These results are notable but come with important caveats. The study was retrospective, meaning researchers looked back at existing records rather than running a controlled experiment. There was no placebo group, so it’s impossible to say how much improvement came from the magnetic stimulation itself versus other factors in the treatment program, the passage of time, or simply the expectation of getting better. The sample was also small, with only 18 participants completing the program.
Evidence for Autism
MeRT is heavily marketed to parents of autistic children, with providers frequently claiming improvements in speech, eye contact, and sleep. The evidence here is far weaker. No large-scale studies have demonstrated significant differences between MeRT and a placebo for autism symptoms. The Association for Science in Autism Treatment noted in a detailed review that Wave Neuroscience, the company behind MeRT, has not published or disclosed any clinical trial results related to MeRT and autism.
Many parents have reported being drawn to MeRT based on provider claims about speech development and improved eye contact, but no peer-reviewed, science-based evidence currently supports these claims. This is an important distinction from the PTSD data: while the military studies are limited, they at least exist in published form. For autism, published clinical evidence is essentially absent.
Safety and Side Effects
MeRT uses the same basic technology as standard rTMS, so its safety profile is similar. The most common side effects are temporary headache and discomfort at the stimulation site. Seizure is the only severe adverse effect consistently linked to transcranial magnetic stimulation, but it has been exceedingly rare since safety guidelines for treatment parameters were established in 1998.
Certain people cannot receive any form of TMS. Standard exclusion criteria include:
- Cardiac pacemakers or implanted medical pumps
- Non-removable metal in or near the head, such as shrapnel, surgical clips, or certain dental implants
- Internal metal above the upper chest
- History of seizures or epilepsy
- Significant brain or head trauma (evaluated case by case)
Regulatory Status
This is where many people get confused. The TMS devices used in MeRT sessions are FDA-cleared hardware, meaning the machines themselves have been approved for certain uses like treatment-resistant depression. But MeRT as a specific protocol, with its individualized frequencies and EEG-guided targeting, is not separately FDA-approved. The distinction matters: providers are using cleared equipment in an off-label way. Patients who have undergone MeRT for autism have acknowledged in FDA adverse event reports that the treatment is “still not FDA approved and is still a largely experimental form of therapy.”
This doesn’t mean MeRT is necessarily unsafe or ineffective, but it does mean the level of regulatory scrutiny applied to it is lower than what most people assume when they hear a treatment involves “FDA-cleared” technology. If you’re considering MeRT, ask specifically what condition the device is cleared for and whether the protocol being offered to you has been tested in controlled trials for your particular condition.